Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 14, 2021 Filed Jan 15, 2021 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,883 | $19.25 | $228,741.81 |
DisclosureSEC source: 0001061983-21-000020 · edgardoc.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,441 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,883 | $9.42 | $111,937.86 |
DisclosureSEC source: 0001061983-21-000020 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 617 | $19.25 | $11,876.94 |
DisclosureSEC source: 0001061983-21-000020 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,441 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 617 | $9.42 | $5,812.14 |
DisclosureSEC source: 0001061983-21-000020 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| December 10, 2020 Filed Dec 10, 2020 22:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,052 | $20.13 | $21,176.76 |
DisclosureSEC source: 0001061983-20-000185 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,441 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,470 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,231 | $17.15 | $21,111.65 |
DisclosureSEC source: 0001061983-20-000177 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,951 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 1,980 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| October 08, 2020 Filed Oct 8, 2020 21:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,258 | $17.45 | $21,952.10 |
DisclosureSEC source: 0001061983-20-000169 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,182 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 3,211 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 20:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 995 | $22.85 | $22,735.75 |
DisclosureSEC source: 0001061983-20-000149 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,440 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 4,469 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 21:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 599 | $21.85 | $13,088.15 |
DisclosureSEC source: 0001061983-20-000139 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,435 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 5,464 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| July 09, 2020 Filed Jul 11, 2020 00:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,587 | $26.96 | $42,785.52 |
DisclosureSEC source: 0001061983-20-000125 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,034 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on March 31, 2020. F2 · balance_after: Includes 6,063 shares of common stock purchased pursuant to the Issuer's 2015 Employee Stock Purchase Plan (ESPP). Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 79,146 | $14.40 Strike: $14.40 | $1,139,702.40 |
DisclosureSEC source: 0001061983-20-000063 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,146 Underlying: Common Stock · 79,146 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 10,854 | $14.40 Strike: $14.40 | $156,297.60 |
DisclosureSEC source: 0001061983-20-000063 · edgardoc.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,854 Underlying: Common Stock · 10,854 shares Expires 2030-03-05 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000063 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,621 F1 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:44 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,075 | $13.94 | $28,925.50 |
DisclosureSEC source: 0001061983-20-000050 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,621 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/28/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 5,533 | $13.94 | $77,130.02 |
DisclosureSEC source: 0001061983-20-000046 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,696 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/27/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 20:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 7,121 | $14.07 | $100,156.87 |
DisclosureSEC source: 0001061983-20-000038 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,229 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on 02/26/2020 and does not represent a sale by the reporting person. F2 · balance_after: Includes up to 5,135 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 21:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $9.80 | $14,700.00 |
DisclosureSEC source: 0001061983-19-000071 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,350 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 22:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $9.98 | $14,970.00 |
DisclosureSEC source: 0001061983-19-000065 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,850 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $11.22 | $16,830.00 |
DisclosureSEC source: 0001061983-19-000061 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 20:48 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $13.69 | $20,531.25 |
DisclosureSEC source: 0001061983-19-000057 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $13.52 | $20,280.00 |
DisclosureSEC source: 0001061983-19-000053 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 23:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $11.26 | $16,890.00 |
DisclosureSEC source: 0001061983-19-000048 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,567 Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:37 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $10.31 | $15,462.75 |
DisclosureSEC source: 0001061983-19-000044 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| May 02, 2019 Filed May 3, 2019 21:34 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $8.29 | $12,429.75 |
DisclosureSEC source: 0001061983-19-000030 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $8.31 | $12,465.00 |
DisclosureSEC source: 0001061983-19-000028 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 21:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $5.98 | $8,970.00 |
DisclosureSEC source: 0001061983-19-000026 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| February 26, 2019 Filed Mar 4, 2019 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 66,075 | $7.14 Strike: $7.14 | $471,775.50 |
DisclosureSEC source: 0001061983-19-000024 · edgardoc.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,075 Underlying: Common Stock · 66,075 shares Expires 2029-02-26 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| February 26, 2019 Filed Mar 4, 2019 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 13,925 | $7.14 Strike: $7.14 | $99,424.50 |
DisclosureSEC source: 0001061983-19-000024 · edgardoc.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,925 Underlying: Common Stock · 13,925 shares Expires 2029-02-26 F2 · derivative.exercise_date: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant. Read SEC document |
| February 26, 2019 Filed Mar 4, 2019 21:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-19-000024 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,067 F1 · deemedExecutionDate: This award shall vest over three years in annual installments: 40% one year from the date of grant, 40% two years from the date of grant and 20% three years from the date of grant. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $7.28 | $10,920.00 |
DisclosureSEC source: 0001061983-19-000017 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| January 10, 2019 Filed Jan 12, 2019 00:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $7.31 | $10,965.00 |
DisclosureSEC source: 0001061983-19-000009 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 21:56 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $7.38 | $11,070.00 |
DisclosureSEC source: 0001061983-18-000055 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 21:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $6.68 | $10,020.00 |
DisclosureSEC source: 0001061983-18-000051 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 15:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $9.14 | $13,710.00 |
DisclosureSEC source: 0001061983-18-000047 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $8.00 | $12,000.00 |
DisclosureSEC source: 0001061983-18-000045 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 21:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $6.85 | $10,275.00 |
DisclosureSEC source: 0001061983-18-000041 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,500 | $9.05 | $13,575.00 |
DisclosureSEC source: 0001061983-18-000039 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,567 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 00:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,000 | $8.95 | $26,850.00 |
DisclosureSEC source: 0001061983-18-000036 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,067 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2018. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 00:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 4,149 | $7.75 | $32,154.75 |
DisclosureSEC source: 0001061983-18-000016 · edgardoc.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,072 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 00:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 8,970 | $7.75 | $69,517.50 |
DisclosureSEC source: 0001061983-18-000016 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,221 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 00:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 25,000 | $0.00 | $25.00 |
DisclosureSEC source: 0001061983-18-000016 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,191 Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 61,886 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-18-000016 · edgardoc.xml · derivative · entry 6 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,886 Underlying: Common Stock · 61,886 shares Expires 2028-02-27 F2 · derivative.exercise_date: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 13,114 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-18-000016 · edgardoc.xml · derivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,114 Underlying: Common Stock · 13,114 shares Expires 2028-02-27 F2 · derivative.exercise_date: When the ISO and NQ dated 02/27/2018 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/27/2022. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:12 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 40,000 | $0.00 | $40.00 |
DisclosureSEC source: 0001061983-18-000016 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,191 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/27/2019, 40% on 02/27/2020 and 20% on 03/01/2021. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 694 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 24 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 694 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 694 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 23 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694 Underlying: Common Stock · 694 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,639 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 22 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,639 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,639 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · derivative · entry 21 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639 Underlying: Common Stock · 2,639 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 843 | $13.80 | $11,633.40 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 20 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,191 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 100 | $13.80 | $1,380.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 19 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,034 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.